Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Kura

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Nihon Ganka Kiyo|June 1, 1971
[The VER in patients with homonymous hemianopia]Yone, Y kura
Ryoikibetsu Shokogun Shirizu|December 16, 1998
[Cutaneous pseudolymphoma]Y Kura, U Sawada, T Ochiai
Nihon Rinsho. Japanese Journal of Clinical Medicine|March 31, 2000
[Treatment of intermediate and high grade non-Hodgkin's lymphoma]T Yamazaki, Y Kura, U Sawada
Nihon Rinsho. Japanese Journal of Clinical Medicine|March 31, 2000
[Phenotypic classification of malignant lymphoma]Y Kaneita, K Yasukawa, Y Kura, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|September 1, 1995
[Daily oral low-dose etoposide therapy for aged patients with relapsed aggressive lymphoma]Y Kura, U Sawada, Y Satoh, et al.
The Journal of International Medical Research|July 1, 1997
Antithymocyte globulin for a patient with systemic lupus erythematosus complicated by severe pancytopeniaY Morishita, Y Matsukawa, Y Kura, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|March 1, 1995
[Long term remission following relapsed CNS lymphoma]Y Kura, U Sawada, I Tsuboi, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 15, 2000
[Merocyanine 540-mediated photodynamic therapy inhibits P-glycoprotein (P-gp) activity in adriamycin-resistant K562 cells]Y Sato, T Yamazaki, K Yasukawa, et al.
International Journal of Hematology|August 1, 1992
Treatment of diffuse non-Hodgkin's lymphoma with combined chemotherapy using methotrexate, adriamycin, cyclophosphamide, vincristine, prednisolone and bleomycin (MACOP-B)U Sawada, T Yamazaki, K Suzuki, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|November 1, 1992
[Complete remission with MEC regimen of acute myeloid leukemia (M4) secondary to 5-year treatment of non-Hodgkin lymphoma]Y Satoh, A Sakuma, I Tuboi, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Nihon Ganka Kiyo|June 1, 1971
[The VER in patients with homonymous hemianopia]Yone, Y kura
Ryoikibetsu Shokogun Shirizu|December 16, 1998
[Cutaneous pseudolymphoma]Y Kura, U Sawada, T Ochiai
Nihon Rinsho. Japanese Journal of Clinical Medicine|March 31, 2000
[Treatment of intermediate and high grade non-Hodgkin's lymphoma]T Yamazaki, Y Kura, U Sawada
Nihon Rinsho. Japanese Journal of Clinical Medicine|March 31, 2000
[Phenotypic classification of malignant lymphoma]Y Kaneita, K Yasukawa, Y Kura, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|September 1, 1995
[Daily oral low-dose etoposide therapy for aged patients with relapsed aggressive lymphoma]Y Kura, U Sawada, Y Satoh, et al.
The Journal of International Medical Research|July 1, 1997
Antithymocyte globulin for a patient with systemic lupus erythematosus complicated by severe pancytopeniaY Morishita, Y Matsukawa, Y Kura, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|March 1, 1995
[Long term remission following relapsed CNS lymphoma]Y Kura, U Sawada, I Tsuboi, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 15, 2000
[Merocyanine 540-mediated photodynamic therapy inhibits P-glycoprotein (P-gp) activity in adriamycin-resistant K562 cells]Y Sato, T Yamazaki, K Yasukawa, et al.
International Journal of Hematology|August 1, 1992
Treatment of diffuse non-Hodgkin's lymphoma with combined chemotherapy using methotrexate, adriamycin, cyclophosphamide, vincristine, prednisolone and bleomycin (MACOP-B)U Sawada, T Yamazaki, K Suzuki, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|November 1, 1992
[Complete remission with MEC regimen of acute myeloid leukemia (M4) secondary to 5-year treatment of non-Hodgkin lymphoma]Y Satoh, A Sakuma, I Tuboi, et al.
Pageof 2